QuidelOrtho Corporation
NASDAQ•QDEL
CEO: Mr. Joseph M. Busky CPA
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1991-02-01
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Contact Information
Market Cap
$1.46B
P/E (TTM)
-1.3
58.6
Dividend Yield
--
52W High
$41.40
52W Low
$19.50
52W Range
Rank39Top 39.1%
4.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$723.60M+0.00%
4-Quarter Trend
EPS
-$1.95+0.00%
4-Quarter Trend
FCF
$86.60M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Revenues Decline Total revenues $2.73B USD, down 2% in 2025; prior year saw 7% revenue decrease compared to 2023.
Net Loss Significantly Improved Net loss $(1.13B) USD in 2025, significantly improving from $(2.05B) USD loss recorded in the prior year.
Major Goodwill Impairment Charges Recognized $700.7M goodwill impairment charge in 2025, following $1.8B USD impairment recorded during 2024.
Restructuring Charges Incurred $263.6M restructuring, integration, and other charges recorded in 2025; U.S. Donor Screening wind-down impacted revenue.
Risk Factors
Intense Industry Competition Highly competitive industry nature risks losing market share or failing to meet customer expectations regarding product performance.
Supply Chain Disruptions Risk Interruptions and delays in raw material supply or manufacturing could adversely affect operations and financial performance.
Regulatory Compliance Exposure Failure to comply with complex FDA regulations or healthcare fraud/abuse laws risks penalties and operational restrictions.
High Indebtedness Level High indebtedness of $2.65B USD limits operational flexibility and increases vulnerability to variable interest rate fluctuations.
Outlook
Optimization Plan Execution Focus Focus on executing multi-year Optimization Plan to realign costs and achieve $50M net cost savings through 2027.
Strategic Portfolio Refocusing Strategic refocusing includes discontinuing SAVANNA platform development and intent to acquire LEX Diagnostics in 2025.
Continued R&D Investment Continued investment in R&D for product expansion, new platform capabilities, and advanced digital integrations expected.
Sufficient Short-Term Liquidity Current cash $169.8M USD and RCF availability sufficient to fund near-term capital and operating needs for next 12 months.
Peer Comparison
Revenue (TTM)
$3.68B
$2.73B
$1.52B
Gross Margin (Latest Quarter)
100.0%
92.2%
90.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| EWTX | $3.01B | -17.4 | -32.0% | 0.7% |
| TWST | $2.98B | -38.8 | -16.6% | 28.8% |
| XRAY | $2.66B | -4.4 | -35.2% | 45.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.5%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data